BigOmics is a technology company.
BigOmics has raised $1.0M across 1 funding round.
BigOmics has raised $1.0M in total across 1 funding round.
BigOmics has raised $1.0M in total across 1 funding round.
BigOmics's investors include Draper Associates, Kima Ventures, KRM Interests LLC, Magical Capital.
BigOmics Analytics is a Swiss biodata analytics startup founded in 2018, specializing in user-friendly platforms that enable biologists to visualize, analyze, and interpret complex omics data like RNA-seq, proteomics, and multi-omics datasets[1][2][3][5]. Its flagship product, Omics Playground, serves life scientists in academia, biotech, and pharma by simplifying data analysis from weeks to minutes, reducing R&D costs, and accelerating discoveries in precision medicine, cancer research, neurodegenerative diseases, and immunology[1][3][5][6]. The company supports over 6,000 researchers globally, with 60+ enterprise clients, and has raised 2.7M CHF (including a recent USD 1.6M round) to expand its tools and market reach[2][4].
BigOmics Analytics emerged as a 2018 spin-off from the Institute of Oncology Research (IOR) and Institute for Research in Biomedicine (IRB), both affiliated with the University of Italian Switzerland (USI) in Ticino, Lugano[2]. Co-founders Ivo Kwee (CTO) and Murodzhon (Murat) Akhmedov (CEO), leveraging their expertise in bioinformatics and biology, launched the first product, Omics Playground, in 2019 to address the pain of cumbersome omics analysis tools[2][4][5]. Early traction came quickly: by 2021, it secured 2.7M CHF in funding and enterprise clients, growing to support 1,500+ scientists; a 2025 USD 1.6M round from Diffusion Capital Partners, SICTIC angels, and TiVentures validated its momentum amid surging omics data volumes[2][4].
BigOmics rides the omics data explosion in precision medicine, where genomics, proteomics, and multi-omics generate vast datasets but overwhelm traditional tools, slowing breakthroughs in cancer, immunology, and neurodegeneration[4][5]. Timing is ideal amid AI-driven biotech booms and post-2020 data surges, with market forces like rising R&D costs (addressed via 82% time savings) and demand for reproducible, collaborative platforms favoring accessible solutions over expert-only software[1][6]. It influences the ecosystem by democratizing analysis for 6,000+ researchers, bridging academia-industry gaps, and enabling faster insights—positioning Switzerland's Ticino as a biodata hub while challenging fragmented tools from incumbents[2][4].
BigOmics is poised to dominate omics analytics as a "go-to platform," fueled by its latest USD 1.6M raise for product acceleration, new markets, and AI enhancements to handle real-time multi-omics[4]. Trends like exploding public datasets, immuno-oncology needs, and precision medicine mandates will propel growth, potentially expanding to 100k+ users and deeper pharma integrations. Its influence may evolve from startup disruptor to infrastructure standard, empowering labs worldwide to cut discovery timelines and drive cures—fast-tracking the data-driven biology revolution that began in a Swiss research institute.
BigOmics has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $1.0M Seed | Draper Associates, Kima Ventures, KRM Interests LLC, Magical Capital |